- Q3 2026 revenue reached $32.9M, while GAAP diluted EPS swung to a loss of $(0.04) from $0.01 in prior year.
- Operating expenses increased, driving an operating loss of $(1.5M) for the quarter.
- Full-year 2026 revenue guidance maintained at $100.5M to $111.0M.
Signal #151072 · SEC 8-K
$GYRE SEC Filing Alert & Real-Time AI Stock Impact Analysis
Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).
FAQ: $GYRE filing catalyst
Why did $GYRE trigger an AI stock catalyst alert?
$GYRE triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: -3.5/10). Headline: Gyre Therapeutics Reports Q3 2026 Loss of $(0.04) Per Share, Affirms FY26 Revenue Guidance. Key points: - Q3 2026 revenue reached $32.9M, while GAAP diluted EPS swung to a loss of $(0.04) from $0.01 in prior year. - Operating expenses increased, driving an operating loss of $(1.5M) for the quarter. - Full-year 2026 revenue guidance maintained at $100.5M to $111.0M.
How did $GYRE stock react after the SEC filing?
After the SEC 8-K for $GYRE, observed market reaction: T0 price $4.01. Past moves do not guarantee future results.
Where can I get real-time $GYRE SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $GYRE via Telegram and the VIP Web Terminal from €10/month.